文献速递消化道肿瘤与早癌消化内镜

高性能生物标志物检测与粪便免疫化学检测用于无创结直肠癌筛查的成本效益

Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-07-18

研究用MISCAN-Colon微模拟模型,比较不同性能特征的假想生物标志物检测与粪便免疫化学检测(FIT)用于平均风险人群结直肠癌筛查的成本效益。每1000名55-75岁受试者每两年一次FIT筛查获得84.9个生命年,成本为122,000欧元(137,000美元);FIT单价7欧元(8美元)时,特异性与敏感性均达100%且进展期腺瘤敏感性53%的生物标志物检测单价不应超过51欧元(57美元)。在结肠镜资源有限或新检测 uptake 更高时,该阈值可升至200欧元(224美元)以上。

要点

  • FIT每轮筛查估计遗漏27%-47%的结直肠癌和70%-80%的进展期腺瘤。
  • 每1000名55-75岁受试者每两年一次FIT筛查获得84.9个生命年,成本122,000欧元(137,000美元)。
  • 总体性能提高的生物标志物检测要具有成本效益,其单价不应超过FIT单价的7倍。

核心结论

  • 总体性能提高的生物标志物检测要具有成本效益,其单价不应超过FIT单价的7倍;若结肠镜更昂贵或稀缺,或新检测筛查 uptake 更高,该上限会大幅提高。

研究设计与样本

  • 使用MISCAN-Colon微模拟模型,模拟平均风险个体接受FIT筛查与不同性能水平的假想生物标志物检测筛查的效果。
  • 模拟的结直肠癌发病率和分期分布校准至荷兰1999年至2003年(筛查机会出现前)的观察数据。
  • 75岁以下诊断结直肠癌后的生存率基于1985年至2004年结直肠癌相对生存数据;75岁及以上诊断者的生存率经调整以拟合观察到的年龄增长死亡率/发病率比。
  • 年龄别全因死亡率基于2010年荷兰生命表。
  • 假设支付意愿阈值为每获得一个生命年50,000欧元(56,000美元),计算各生物标志物检测相对于FIT具有成本效益的最大单价。

主要发现

  • 对55-75岁受试者每两年一次FIT筛查,每1000名参与者获得84.9个生命年,成本为122,000欧元(137,000美元)。
  • FIT单价为7欧元(8美元)(仅包括试剂盒和分析,不包括组织成本)时,以100%特异性和敏感性检出结直肠癌、并以53%敏感性检出进展期腺瘤的生物标志物检测,其单价不应超过51欧元(57美元)。
  • 在结肠镜容量有限或该检测 uptake 更高的情况下,高性能生物标志物检测的阈值成本可增至200欧元(224美元)以上。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Biomarker assays could increase the accuracy of noninvasive detection of colorectal cancer (CRC); fecal immunochemical tests (FITs) are estimated to miss 27%-47% of CRCs and 70%-80% of advanced adenomas per round of screening. We investigated the conditions under which biomarker screens would be cost-effective compared with FIT screens of average-risk individuals. METHODS: We used the MISCAN-Colon microsimulation model to estimate the effects of various CRC screening test characteristics on life-years gained (LYG) and; age-specific all-cause mortality was based on the 2010 Dutch life tables. Simulated CRC incidence rate and CRC stage distribution were calibrated to observed data in The Netherlands from 1999 through 2003 (before opportunities for screening). Survival rates after diagnosis of CRC at an age younger than 75 years were based on CRC relative survival data from 1985 through 2004; survival for individuals diagnosed at an age of 75 years or older was adjusted to fit the observed age-increasing mortality/incidence ratio. We modeled FIT along with hypothetical biomarker tests with different test performance levels. For each biomarker test we calculated the maximum unit cost for the test to be cost-effective compared with FIT, assuming a willingness-to-pay threshold of €50,000 ($56,000) per LYG. RESULTS: Biennial FIT screening of subjects 55-75 years old provided 84.9 LYG at a cost of €122,000 ($137,000) per 1000 participants. Considering a unit cost of €7 ($8) for FIT (including kit and analysis only, excluding organizational costs), a biomarker test that detects CRC with higher levels of specificity and sensitivity (100%) and advanced adenomas at a proportionally higher level of sensitivity (53%) should never exceed a cost of €51 ($57). The threshold cost could increase to more than €200 ($224) for high-performing biomarker tests in cases of limited colonoscopy capacity or higher uptake of this test. CONCLUSIONS: By using the MISCAN-Colon microsimulation model to estimate effects of CRC screening tests, we found that for a biomarker test with increased overall performance to be cost-effective, it should not exceed 7-fold the unit cost of FIT. This maximum would increase substantially if colonoscopy becomes more expensive or scarce, or if the new test has higher screening uptake. These values could be used to estimate the added value of new biomarkers compared with current FIT screening.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lansdorp-Vogelaar I, Goede SL, Bosch LJW, et al. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. Clin Gastroenterol Hepatol. 2017. PMID: 28733262. doi:10.1016/j.cgh.2017.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。